全文获取类型
收费全文 | 208721篇 |
免费 | 18394篇 |
国内免费 | 6107篇 |
专业分类
耳鼻咽喉 | 1447篇 |
儿科学 | 4011篇 |
妇产科学 | 2197篇 |
基础医学 | 28117篇 |
口腔科学 | 4648篇 |
临床医学 | 20783篇 |
内科学 | 26446篇 |
皮肤病学 | 2169篇 |
神经病学 | 11369篇 |
特种医学 | 4847篇 |
外国民族医学 | 26篇 |
外科学 | 16999篇 |
综合类 | 30676篇 |
现状与发展 | 15篇 |
一般理论 | 27篇 |
预防医学 | 18778篇 |
眼科学 | 4846篇 |
药学 | 25336篇 |
42篇 | |
中国医学 | 12805篇 |
肿瘤学 | 17638篇 |
出版年
2023年 | 2810篇 |
2022年 | 3773篇 |
2021年 | 7062篇 |
2020年 | 6823篇 |
2019年 | 7161篇 |
2018年 | 7090篇 |
2017年 | 6838篇 |
2016年 | 6767篇 |
2015年 | 6686篇 |
2014年 | 11750篇 |
2013年 | 12886篇 |
2012年 | 10740篇 |
2011年 | 12221篇 |
2010年 | 10236篇 |
2009年 | 9996篇 |
2008年 | 10410篇 |
2007年 | 11485篇 |
2006年 | 10422篇 |
2005年 | 10019篇 |
2004年 | 8676篇 |
2003年 | 7769篇 |
2002年 | 5780篇 |
2001年 | 5606篇 |
2000年 | 4628篇 |
1999年 | 4177篇 |
1998年 | 2858篇 |
1997年 | 2684篇 |
1996年 | 2633篇 |
1995年 | 2726篇 |
1994年 | 2370篇 |
1993年 | 2110篇 |
1992年 | 1886篇 |
1991年 | 1638篇 |
1990年 | 1419篇 |
1989年 | 1299篇 |
1988年 | 1257篇 |
1987年 | 976篇 |
1986年 | 768篇 |
1985年 | 903篇 |
1984年 | 921篇 |
1983年 | 581篇 |
1982年 | 731篇 |
1981年 | 607篇 |
1980年 | 528篇 |
1979年 | 449篇 |
1978年 | 351篇 |
1977年 | 306篇 |
1976年 | 335篇 |
1975年 | 220篇 |
1973年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
2.
3.
Guo-Quan Shi Huajun Zhu & Zhen-Guo Yan 《Communications In Computational Physics》2022,31(4):1215-1241
A priori subcell limiting approach is developed for high-order flux reconstruction/correction procedure via reconstruction (FR/CPR) methods on two-dimensional unstructured quadrilateral meshes. Firstly, a modified indicator based on
modal energy coefficients is proposed to detect troubled cells, where discontinuities
exist. Then, troubled cells are decomposed into nonuniform subcells and each subcell has one solution point. A second-order finite difference shock-capturing scheme
based on nonuniform nonlinear weighted (NNW) interpolation is constructed to perform the calculation on troubled cells while smooth cells are calculated by the CPR
method. Numerical investigations show that the proposed subcell limiting strategy on
unstructured quadrilateral meshes is robust in shock-capturing. 相似文献
4.
目的:探讨ICU护士执行身体约束缩减行动的障碍因素,为制定身体约束标准化管理方案提供依据。方法:基于理论域框架(TDF)制定访谈提纲,采用目的抽样法对天津市某三级甲等医院的12名ICU护士进行半结构式访谈,按照TDF的相关领域对转录后的资料进行归类,用内容分析法对访谈资料进行分析。结果:ICU护士对身体约束缩减行动理解存在偏差、对约束替代措施内容的不熟悉是其执行身体约束缩减行动的障碍因素之一;身体约束缩减方案评估工具、决策流程的不规范对缩减约束行动的开展造成了一定阻碍;环境因素的限制及对缩减约束结果的担忧,使ICU护士没有足够的信心去执行;科室缺乏支持缩减约束的组织氛围,难以引起护士对执行约束缩减行动的重视,进而削减执行的动力。结合理论域框架将上述因素分别归属为知识、自我效能、环境背景和资源、社会影响、行为规范5个领域。结论:知识、自我效能、环境背景和资源、社会影响及行为规范为ICU护士执行身体约束缩减行动的障碍因素。科室要在明确障碍因素的基础上,加强领导层对执行缩减约束的重视和支持。制定缩减约束评估决策规范化流程以及培训方案,倡导团队协作,创造支持身体约束缩减行动的组织氛围,坚定ICU护士执行缩减约束的信心,促进身体约束缩减行动的持续实施。 相似文献
5.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
6.
Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(5):319-325
BackgroundDespite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outcomes in real-world practice are dismal. We utilized National Cancer Database (NCDB) to explore utilization of multiagent therapy in APL and identify any disparities in treatment in real-world practices.Patients and MethodsNCDB categorizes use of systemic chemotherapy into single agent versus multiagent therapy. Some patients received hormonal therapy, immunotherapy, and unknown therapy; details of these treatments could not be ascertained. We therefore used multiple logistic regression analysis to evaluate effects of covariates on the probability of multiagent therapy use in 6678 patients.ResultsCompared to patients >60 years, patients aged 0 to 18 years (hazard ratio[HR] 3.2, 95% confidence interval [CI] 1.8-5.5, P< .0001), 19 to 40 years (HR 1.6, 95% CI 1.03-2.54, P= .03), and 41 to 60 years (HR 1.6, 95% CI 1.3-1.9, P< .0001) were more likely to receive multiagent therapy. Patients with Charlson comorbidity index (CCI) of 0 (HR 1.6, 95% CI 1.2-2.3, P= .001) and CCI of 1 (HR 1.4, 95% CI 1.0-1.9, P= .04) had a higher likelihood of receiving multiagent therapy than patients with CCI ≥ 3. Patients treated at academic cancer centers, compared to those treated at community cancer center (HR 0.5, 95% CI 0.3-0.7, P= .001), comprehensive community cancer center (HR 0.7, 95% CI 0.6-0.8, P< .0001), and integrated network cancer center (HR 0.8, 95% CI 0.6-0.9, P= .02) were more likely to be treated with multiagent therapy. Compared to the patients with private insurance, those with Medicaid had increased likelihood (HR 1.2, 95% CI 1.0-1.4, P= .04) whereas uninsured patients had a lower likelihood of receiving multiagent therapy (HR 0.6, 95% CI 0.5-0.8, P= .0005).ConclusionTo our knowledge, this study is the first and the largest scale analysis of treatment practices in APL in real-world practices. Our findings highlight significant disparities in treatment of APL based on age, insurance, and health-system factors. 相似文献
7.
8.
9.
10.